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mTOR is a kinase complex involved in cell growth, proliferation, survival, metab-
olism and migration. The aberrant activation of mTOR has been previously demon-
strated in glioblastoma multiforme (GBM), making it an interesting target for thera-
peutic approaches [1]. Unfortunately, the attempts to block mTOR activity made so 
far had disappointing clinical efficacy, as the mTOR inhibitor Rapamycin and analogs 
only target mTOR complex 1 (mTORC1) while mTOR actually exists in two distinct 
complexes, namely mTORC1 and mTOR complex 2 (mTORC2) that differ in terms of 
both regulation mechanisms and functions [2,3]. mTORC1 is inhibited by Rapamycin 
and acts as a downstream effector of the PTEN/PI3K/Akt pathway, linking growth 
factors, amino acids, ATP and O2 signals to protein translation, cell growth, prolif-
eration and survival. Differently, mTORC2 is insensible to Rapamycin and acts as an 
upstream activator of Akt via phosphorylation of serine 473 [3]. To analyze the con-
tribution of mTORC1/2 to GBM biology, we studied the in vitro effect of PP242, a 
novel mTORC1/2 inhibitor, on glioma cell lines of different malignancy degree, and 
compared it to the effect of Rapamycin and of the irreversible PI3K inhibitor, Wort-
mannin. 
Our results suggest that the inhibition of both mTOR complexes with PP242 
induces sustained levels of autophagy that causes G0/G1 cell cycle arrest and a sig-
nificantly reduction of cell viability, proliferation and migration. Additionally, we 
observed that administration of PP242 in U87MG cell line prevents stem cell growth, 
which results in the inhibition of neurospheres formation. This data confirms the piv-
otal role of mTOR in glioblastoma cells biology and expand upon this evidence sug-
gesting a prominent role of the mTOR complex 2 in glioblastoma cell growth, migra-
tion and survival, and indicate that the mTORC2 might represent clinically valuable 
target in GMB.
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